Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 5/20 | 0.50 |
| ▸ | GLP1R | P43220 | 5/20 | 0.49 |
| ▸ | CD47 | Q08722 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CTSH | P09668 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30093071 | 0.99 | C5AR1 (0.54) | C5AR1KISS1RGLP1RCD47CTSL | |
| SCHEMBL30093023 | 0.96 | KISS1R (0.54) | C5AR1KISS1RGLP1R | |
| SCHEMBL30093064 | 0.95 | C5AR1 (0.53) | C5AR1KISS1RGLP1RCD47CTSL | |
| SCHEMBL30093066 | 0.95 | C5AR1 (0.53) | C5AR1KISS1RGLP1RCD47CTSL | |
| SCHEMBL30093002 | 0.95 | C5AR1 (0.55) | C5AR1KISS1RGLP1RCD47CTSL | |
| SCHEMBL30130535 | 0.94 | C5AR1 (0.61) | C5AR1GLP1RCD47 | |
| SCHEMBL30130567 | 0.94 | C5AR1 (0.61) | C5AR1GLP1RCD47 | |
| SCHEMBL30093087 | 0.94 | C5AR1 (0.60) | C5AR1GLP1RCD47 | |
| SCHEMBL30148455 | 0.92 | KISS1R (0.56) | KISS1RCD47PRMT1SIRT5 | |
| SCHEMBL30093096 | 0.92 | KISS1R (0.56) | KISS1RCD47PRMT1SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | ANYGEN CO., LTD. (KR) | 2023-09-14 | — | — | US | claimed |
| EP-4129064-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | Anygen Co., Ltd. (KR) | 2023-02-08 | — | — | EP | claimed |
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | ANYGEN CO., LTD. (KR) | 2023-09-14 | — | — | US | disclosed |
| EP-4129064-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | Anygen Co., Ltd. (KR) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287044-A1 | NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF | VIP, CUTA, LNPEP | C5AR1 1231/4885KISS1R 1140/4885GLP1R 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.